Medinex Limited Overview
Medinex Limited is a Singapore-based, Catalist-listed holding company that provides outsourced professional support to private medical practices, and to a lesser extent to non-healthcare SMEs. Its core proposition is a one-stop platform for doctors who want to start, run and grow a clinic: setting up the clinic and handling licensing, accounting, tax, corporate secretarial, HR and payroll, and procuring pharmaceuticals and medical consumables. Its stated vision is to be the preferred multi-disciplinary support platform for its clients. Four reported segments generated S$12.4m of revenue in FY2026. The two high-margin service segments (Medical Support and Business Support) generate almost all segment profit. Pharmaceutical procurement is loss-making after impairment, and Medical Services was discontinued on 31 March 2026. The group is net-cash, pays a steady dividend of 1.68 Singapore cents per share, and faces pricing pressure, consolidation of private healthcare, tighter Integrated Shield Plan rules and AI-driven disruption of transactional bookkeeping.
Company's own description (Annual Report 2026)
Paraphrasing AR2026's corporate profile: Medinex describes itself as a Singapore-based medical support services provider specialising in professional support services to medical clinics. Its medical support scope covers overseeing clinic set-ups, helping obtain clinic licences, and business support such as accounting, tax agent services, HR management and corporate secretarial services. It also provides X-ray, pre-employment check-up and health screening services (the Medical Services segment, discontinued from 31 March 2026). Its pharmaceutical services help clients procure medical and pharmaceutical products from authorised distributors in Singapore. As an ancillary activity, it provides accounting, tax and corporate services to companies outside healthcare, with clients in food and beverage, retail, education and beauty. Medinex is an Accredited Training Organisation (ATO) for the Chartered Accountant (Singapore) designation. Its mission statement frames it as a trusted partner helping clients "start, sustain and succeed".
Independent characterisation
Economically, Medinex is a small professional-services roll-up with a healthcare vertical focus. Since its 2018 IPO it has grown mainly by buying small, founder-run accounting, corporate-secretarial and HR consultancies (Ark Leadership & Learning, the SKI group, AccTax, Carlin Management Services) and putting them on a shared back office, including a lower-cost team in Malaysia. Healthcare enters the model in three ways:
-
Clinic-facing professional services. Clinic set-up projects, licensing support, and recurring compliance work for general practitioners (GPs) and specialists. This is the Medical Support Services segment.
-
Pharmaceutical procurement. Through Nex Healthcare Pte. Ltd., Medinex buys medicines and consumables from authorised Singapore distributors and delivers them to clinics using two company vans. This is a low-margin trading activity, and in FY2026 it was exposed to customer concentration.
-
Direct medical services. X-ray, health screening and pre-employment checks through Sen Med and later Express Medical. This line shrank from S$1.95m of revenue in FY2022 to S$0.49m in FY2026 and was discontinued when Express Medical was sold on 31 March 2026.
Revenue model
| Revenue type (as disclosed) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Service fees (S$'000) | 8,768 | 9,025 | 9,132 |
| Sale of medical and pharmaceutical products (S$'000) | 3,308 | 3,288 | 2,789 |
| Provision of medical services (S$'000) | 509 | 500 | 493 |
| Total revenue (S$'000) | 12,585 | 12,813 | 12,414 |
| Timing of revenue recognition | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Point in time (S$'000) | 11,493 | 11,551 | 11,401 |
| Over time (S$'000) | 1,092 | 1,262 | 1,013 |
Source: FY2025 and FY2026 results announcements, Note 4.2 (disaggregation of revenue).
Source: FY2025 and FY2026 results announcements, Note 4.2.
In FY2026 the mix was about 74% professional service fees, 22% product resale and 4% medical services. There is no licensing or software subscription revenue. Much of the service-fee revenue recurs in practice, because annual compliance engagements (statutory accounts, tax filings, AGM secretarial work, payroll) repeat each year, even though most is recognised at a point in time. The company does not disclose a recurring-revenue percentage or customer retention metrics.
Value-chain position and customers
Value-chain position: Medinex is a downstream service intermediary. It does not manufacture products or employ treating doctors at scale. In pharmaceuticals it is a procurement and distribution intermediary between authorised distributors and clinics; all FY2026 procurement spending was with local suppliers (AR2026).
Customer types: Private GPs and specialists in Singapore's primary and secondary care sectors; clinic owners setting up new practices; corporates buying health screening and pre-employment services (until March 2026); and SMEs outside healthcare (F&B, retail, education, beauty) buying accounting, tax and corporate secretarial services.
End-markets: Singapore private healthcare and Singapore SME corporate services. Malaysia is used mainly as a support and cost base (Medinex Corporate Services Sdn. Bhd.). Revenue by geography is not disclosed.
Strategy
Stated strategic themes (AR2026 Chairman and CEO message)
Paraphrasing AR2026, management's priorities are to:
-
Expand service offerings towards higher-value advisory and integrated solutions.
-
Use technology, including AI, to improve efficiency and competitiveness.
-
Strengthen workforce capabilities in line with changing customer needs.
-
Pursue growth through strategic partnerships and initiatives.
The FY2026 results commentary adds that the group needs to transform its business model by adopting AI-driven solutions and moving from traditional services towards higher-value advisory and operational support. Management's message is that FY2026 was a year of "resilience amid transition".
Initiatives in the last 24 months
| Initiative | Timing | Detail and target | Status | Source |
|---|---|---|---|---|
| Exit from direct medical services | FY2025–FY2026 | Sen Med Holdings struck off (29 May 2025); Express Medical sold (31 March 2026); Medical Services segment discontinued | Completed | AR2026 |
| Office consolidation | FY2026–FY2027 | From 7 to 4 locations in FY2026; target 3 in FY2027 | In progress | AR2026 |
| Digitising tax and compilation | FY2026–FY2027 | Move tax and compilation work to an online platform | Work in progress; completion targeted for FY2027 | AR2026 |
| E-signing for incorporations | FY2027 | Replace hard-copy signing with electronic signing; store documents on SharePoint | Planned | AR2026 |
| Integrating subsidiaries' manpower | FY2026–FY2027 | Integrate Carlin's workflows; consolidate manpower across subsidiaries | Work in progress | AR2026 |
| Business Manager model | FY2026 | Every business unit now led by a Business Manager | Completed | AR2026 |
| Malaysia cost base | FY2025–FY2026 | Hire support staff in Malaysia | Ongoing | FY2025 results; AR2026 |
| Payment support service | FY2025 | New recurring service at MDX Advisory (about S$0.33m revenue uplift) | Launched | FY2025 results |
| Data Protection Trustmark | FY2027 | Target certification by 31 March 2027 | Planned | AR2026 |
| Board gender diversity | By FY2028 | At least 40% female directors | Not yet met (20%) | AR2026 |
| Quoted investment portfolio rotation | FY2026 | Sold Singapore Paincare and Niks Professional holdings (gain S$184k; proceeds S$531k) | Completed | FY2026 results |
Medium-term targets and guidance
Medinex publishes no financial guidance or medium-term targets. Each results announcement states that no forecast or prospect statement has been disclosed. Its dividend has been 1.68 Singapore cents per share for five consecutive years, but there is no formal dividend policy.
Products & Services
Medinex does not publish a priced product list, version history or flagship brand names beyond its subsidiaries. The catalog below is built from disclosures in AR2026, the FY2023–FY2026 results announcements and AR2020. Pricing models are not publicly disclosed for any offering. Where a service is linked to a subsidiary on the basis of the disclosed activity rather than an explicit statement, it is marked "(inferred)".
Medical Support Services
| Offering | Description and capabilities | Target customer | Entity | Year / status |
|---|---|---|---|---|
| Turnkey clinic set-up | End-to-end management of new clinic establishment: premises, fit-out coordination, licensing applications, operational readiness. AR2026 describes it as turnkey solutions plus strategic advice. | New GP and specialist practices | Medinex Healthcare Pte. Ltd. (MHC secured additional set-up projects in FY2026) | Core since pre-IPO; growth driver in FY2026 |
| Clinic licensing facilitation | Help with applications for relevant clinic licences | New and relocating clinics | MHC / MCS (inferred) | Ongoing |
| Customised operational support for clinics | Value-added support for primary and secondary care clinics; AR2026 notes a shift towards customised services instead of standard packages | Existing GP and specialist clinics | MHC, Nex | Ongoing |
| Clinic accounting, tax and secretarial bundle | Accounting, tax agent, HR and corporate secretarial services sold to clinics | Clinic owners | MCS, MHC (inferred) | Ongoing |
| Related support areas named by management | FY2023 commentary lists clinic set-up support, IT, digital marketing and branding, HR support and financial management support | Doctors | Group | Stated focus areas (FY2023) |
Business Support Services
| Offering | Description and capabilities | Target customer | Entity | Year / status |
|---|---|---|---|---|
| Accounting and compilation | Bookkeeping and compilation of financial statements; migration to an online platform under way (AR2026 target to complete in FY2027) | SMEs including F&B, retail, education and beauty | MCS, MDX Professional Services, Carlin, MDX Advisory (inferred) | Ongoing |
| Tax agent and tax advisory (income tax and GST) | Corporate tax filings and GST advisory led by the Chief Tax Officer, an accredited tax advisor | SMEs, clinics | AccTax Management Consultancy | AccTax founded 2006 |
| Corporate secretarial | Incorporation, statutory filings, AGM documentation (clients sign AGM documents electronically), directorship-related services; electronic signing plus SharePoint storage targeted for FY2027 | SMEs, clinics | MCS, MDX Advisory, Carlin (inferred) | Ongoing; FY2025 commentary notes heavier compliance and due-diligence burden |
| HR management and payroll | HR consulting and client payroll processing (pass-through client payroll costs raised FY2026 employee expense) | SMEs, clinics | Ark Leadership & Learning | Acquired May 2019 |
| Leadership and organisational development training | Leadership and organisation development consulting and training; founder is a Gallup-certified strengths coach and an Enterprise Singapore-recognised consultant | Corporates across Asia | Ark Leadership & Learning | Founded 2014 |
| Payment support service | New recurring revenue stream added about S$0.33m in FY2025 | SME clients | MDX Advisory | Launched FY2025 |
| Accredited training for the CA (Singapore) designation | Medinex is an Accredited Training Organisation for the Chartered Accountant (Singapore) qualification | Accounting trainees | Medinex group | Ongoing |
Pharmaceutical Services
| Offering | Description and capabilities | Target customer | Entity | Year / status |
|---|---|---|---|---|
| Pharmaceutical and medical product procurement | Buys medicines and medical consumables from licensed, authorised Singapore distributors; top three suppliers evaluated regularly; drug labels approved by the Health Sciences Authority; 100% of procurement spend with local suppliers | GP and specialist clinics | Nex Healthcare Pte. Ltd. | Ongoing; a major customer was lost in FY2026 and a major contract is expected to expire in July 2026 |
| Medication delivery to clinics | Two company-owned vans deliver medication to designated clinics (4,372 litres of petrol consumed in FY2026) | Clinics | Nex Healthcare | Ongoing |
Medical Services (discontinued 31 March 2026)
| Offering | Description | Target customer | Entity | Status |
|---|---|---|---|---|
| Health screening packages | Individual and corporate health screening | Individuals, corporates | Sen Med group, then Express Medical | Discontinued |
| Diagnostic and X-ray services | Imaging and diagnostics | Patients, employers | Sen Med / Express Medical | Discontinued |
| Pre-employment checks and pass/permit medicals | Medical reviews for employment passes, student passes and work permits | Employers, foreign workers, students | Sen Med / Express Medical | Discontinued |
| Vaccination services | Vaccinations | Individuals, corporates | Sen Med / Express Medical | Discontinued |
| Customised corporate healthcare plans | Healthcare plans tailored to organisations | Corporates | Sen Med / Express Medical | Discontinued |
| General practice care | Comprehensive GP-level care | Patients | Sen Med clinics, including The Family Clinic@Towner (sold in FY2024) | Discontinued |
Financial Narrative
Definitions used for derived metrics:
Gross profit (derived): revenue − inventories and consumables used − changes in inventories. The company does not report gross profit. This definition matches Moomoo's aggregator figures for FY2022–FY2024.
EBIT (derived): profit before tax + finance costs. It includes other income, fair-value movements, goodwill impairment and share of JV results.
EBITDA (derived): EBIT + depreciation and amortisation, including right-of-use (lease) depreciation under SFRS(I) 16.
Adjusted net profit (derived): reported net profit excluding goodwill and JV impairments, FVTPL fair-value gains and losses, gains and losses on disposal or derecognition of investments and subsidiaries, and liquidation gains. Tax effects are ignored because these items appear largely non-taxable.
Income statement
Sources: FY2023 results (FY2022–FY2023), FY2025 results (FY2024–FY2025), FY2026 results (FY2026). The FY2024 total profit is shown as 867 in the FY2025 income statement and 868 in its statement of changes in equity (rounding).
Adjusted net profit reconciliation (derived):
-
FY2022: 2,896 − 387 FV gain − 471 derecognition gain + 339 goodwill impairment + 90 JV impairment + 34 disposal loss = 2,501
-
FY2023: 1,689 + 816 FV loss = 2,505
-
FY2024: 867 + 1,008 FV loss + 609 subsidiary disposal loss + 84 investment disposal loss = 2,568
-
FY2025: 2,832 − 15 FV gain + 261 impairment − 7 liquidation gain = 3,071
-
FY2026: 2,225 + 1,596 impairment − 586 FV gain − 184 disposal gain − 17 subsidiary disposal gain + 3 write-off = 3,037
Management's own non-GAAP figure, net profit before goodwill impairment, was S$3.09m in FY2025 and S$3.82m in FY2026 (+24%). That figure still includes FY2026's S$0.77m of fair-value and disposal gains on quoted investments.
Per-share data (Singapore cents)
Sources: results announcements. The FY2022 and FY2023 NAV per share figures were calculated on total equity including non-controlling interests; FY2024 onwards uses equity attributable to owners. The bases therefore differ slightly. Weighted average shares were 131,207,540 (FY2022), 132,691,176 (FY2023–FY2025) and 133,254,590 (FY2026).
Dividend composition:
-
FY2022: interim 0.84 + final 0.84
-
FY2023: interim 0.65 + final 1.03
-
FY2024–FY2026: interim 0.84 + final 0.84
Margins and growth (derived)
The four-year revenue CAGR from FY2022 to FY2026 is 0.9% (derived). In practice the group is ex-growth at the top line.
Commentary:
Gross margin: rose from 71% to 80% because revenue shifted away from product-heavy pharmaceutical and medical-services work towards fee-based professional services.
Reported earnings: swung widely, mainly because of non-operating items: fair-value moves on a quoted equity portfolio (S$2.7m at FY2026), goodwill impairments (FY2022, FY2025 and FY2026), and disposal losses in FY2024.
Adjusted net profit: is much steadier, at about S$2.5m in FY2022–FY2024 and about S$3.0–3.1m in FY2025–FY2026. The step-up came from cost discipline (FY2025 employee costs fell S$0.14m despite higher headcount because more staff were hired in Malaysia) and from the exit from loss-making medical services.
FY2026's second half: shows the pressure building. 2H FY2026 net profit was only S$130k against S$1,423k in 2H FY2025, mainly because the Nex impairment fell entirely in that half. 1H FY2026 profit of S$2,095k was boosted by FVTPL gains.
Balance sheet
The single remaining borrowing at 31 March 2026 is "Term loan I": unsecured, fixed-rate, repayable over 60 months, guaranteed by the company, with S$262k left and all of it due within 12 months. In FY2022 there was also a small revolving working-capital line (S$10k).
Commentary: Goodwill is the largest single asset. It was S$6.75m at FY2026, equal to 41% of equity and 35% of total assets. Against that, cash and fixed deposits (S$5.52m) plus quoted investments (S$2.72m) give S$8.25m of liquid assets, equal to about 31% of the current market capitalisation. After the FY2026 impairment, goodwill by cash-generating unit (CGU) is:
Pre-tax discount rates used in impairment testing fell from 14% across all CGUs in FY2025 to between 8.62% and 11.25% in FY2026. Terminal growth assumptions rose to 2.0–3.0% (from 2.6%). Both changes raise value-in-use estimates, so the headroom in the remaining goodwill depends partly on these more favourable assumptions. This is a point for auditors and investors to watch.
Cash flow
Sources: results announcements, statements of cash flows. FY2022 combines S$2,500k of proceeds and S$2,735k of repayments. FY2024 disposal proceeds are S$80k from subsidiaries plus S$1,764k from FVTPL disposals. FY2026 disposal proceeds are S$78k from Express Medical plus S$531k from FVTPL disposals.
Commentary: The business converts earnings to cash reliably. Operating cash flow has stayed between S$2.7m and S$3.4m a year, and maintenance capex is negligible (under 2% of revenue). After lease payments, however, free cash flow of about S$2.1–2.9m only roughly covers the dividend of about S$2.2–2.5m. FY2026 shareholder returns (dividends of S$2.25m plus a S$0.60m buyback) exceeded FCF after leases. The buyback was not a discretionary return: the shares bought back were transferred to the Carlin vendor as deferred consideration. Dividend capacity at the current 1.68-cent rate therefore depends on keeping adjusted profit at about S$2.5m or more.
Ratios (derived)
Method notes:
-
FY2021 opening owners' equity of S$16,657k (FY2023 results, statement of changes in equity) is used for the FY2022 average.
-
ROIC uses a 17% notional tax rate (Singapore's headline corporate tax rate). Invested capital includes quoted investments.
-
Trade payables are not shown separately in the condensed statements, so DPO uses StockAnalysis aggregator figures for accounts payable (S$0.42m, 0.47m, 0.38m, 0.32m, 0.25m).
-
DIO and DPO relate only to the pharmaceutical and medical activities. The cash conversion cycle is therefore an approximation for a services-heavy group.
Commentary: Returns are high for an asset-light services business once FVTPL losses and impairments are stripped out. The balance sheet has de-levered steadily: bank debt fell from S$2.28m to S$0.26m. Receivable days rose to 67 in FY2026 from 57, even though management cites improved collection; trade receivables grew S$0.28m on lower revenue. This is a minor monitorable.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Ownership | Country | Role (Medinex disclosure, or analyst inference where marked) |
|---|---|---|---|
Medinex Limited | Listed parent | Singapore | Investment holding |
Medinex Corporate Services Pte. Ltd. (MCS) | 100% | Singapore | Corporate and business support services (inferred from name and director roles) |
Medinex Corporate Services Sdn. Bhd. | 100% (via MCS) | Malaysia | Support and back-office team; FY2026 hires were in Malaysia |
Medinex Healthcare Pte. Ltd. (MHC) | 100% | Singapore | Medical support services; clinic set-up projects (FY2026 results) |
MDX Professional Services Pte. Ltd. (formerly Medinex Professional Services) | 100% | Singapore | Professional services; separate goodwill CGU |
Nex Healthcare Pte. Ltd. (Nex) | 100% | Singapore | Pharmaceutical procurement and medical support; headed operationally by COO Lee Kim Hung |
AccTax Management Consultancy Private Limited | 100% | Singapore | Tax and GST advisory and accounting; founded 2006 by Chai Yee Hoi |
Ark Leadership & Learning Pte. Ltd. (Ark LL) | 100% | Singapore | HR consulting, leadership training, client payroll; MD is Valerie Low |
Carlin Management Services Pte. Ltd. | 100% | Singapore | Business support services (acquired 1 April 2022) |
MDX Advisory Pte. Ltd. (formerly Medinex Advisory, formerly SKI Corporate Services) | 100% | Singapore | Business support services, including a payment support service from FY2025 |
Healthcare Essentials Pte. Ltd. (HEPL) | — | Singapore | Equity-accounted; share of profit S$141k in FY2026 |
Sen Med Holdings Pte. Ltd. | Struck off 29 May 2025 | Singapore | Former medical services platform |
Express Medical Pte. Ltd. | Sold 31 March 2026 | Singapore | Former medical services (X-ray and screening) |
Segment Overview
| Segment | What it contains | Status |
|---|---|---|
Medical Support Services | Customised support for GPs and specialists; turnkey clinic set-up and advisory | Continuing |
Business Support Services | Accounting, tax, corporate secretarial, HR and payroll, payment support for SMEs across industries | Continuing |
Pharmaceutical Services | Procurement of medical and pharmaceutical products for Singapore clinics from authorised distributors | Continuing; major Nex contract expiring July 2026 |
Medical Services | Health screening, diagnostic and X-ray services, pre-employment and pass/permit medicals, vaccinations, corporate healthcare plans, GP-level care | Discontinued with effect from 31 March 2026 |
Unallocated | Head-office costs, investment income, share of JV results | Reconciling item |
Segment revenue (SGD K)
| Segment revenue (SGD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Medical Support Services | 3,794 | 3,944 | 4,543 | 4,433 | 4,545 |
Business Support Services | 2,845 | 3,988 | 4,180 | 4,592 | 4,587 |
Pharmaceutical Services | 3,405 | 3,843 | 3,308 | 3,288 | 2,789 |
Medical Services | 1,949 | 1,172 | 509 | 500 | 493 |
Unallocated | 0 | 18 | 45 | 0 | 0 |
Group revenue | 11,993 | 12,965 | 12,585 | 12,813 | 12,414 |
Segment profit before tax (SGD K)
| Segment profit before tax (SGD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Medical Support Services | 2,569 | 2,865 | 3,408 | 3,501 | 3,440 |
Business Support Services | 2,346 | 2,621 | 2,588 | 3,065 | 2,966 |
Pharmaceutical Services | 43 | 17 | -178 | -170 | -437 |
Medical Services | 303 | 100 | -134 | 31 | 26 |
Unallocated | -1,995 | -3,561 | -4,667 | -3,444 | -3,574 |
Group profit before tax | 3,266 | 2,042 | 1,017 | 2,983 | 2,421 |
Segment PBT margin (%) — derived
| Segment PBT margin (%) — derived | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Medical Support Services | 67.7 | 72.6 | 75.0 | 79.0 | 75.7 |
Business Support Services | 82.5 | 65.7 | 61.9 | 66.7 | 64.7 |
Pharmaceutical Services | 1.3 | 0.4 | -5.4 | -5.2 | -15.7 |
Medical Services | 15.5 | 8.5 | -26.3 | 6.2 | 5.3 |
Segment revenue YoY growth (%) — derived
| Segment revenue YoY growth (%) — derived | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Medical Support Services | 4.0 | 15.2 | -2.4 | 2.5 |
Business Support Services | 40.2 | 4.8 | 9.9 | -0.1 |
Pharmaceutical Services | 12.9 | -13.9 | -0.6 | -15.2 |
Medical Services | -39.9 | -56.6 | -1.8 | -1.4 |
Group | 8.1 | -2.9 | 1.8 | -3.1 |
Segment share of group revenue (%) — derived (%)
| Segment share of group revenue (%) — derived (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Medical Support Services | 31.6 | 30.4 | 36.1 | 34.6 |
Business Support Services | 23.7 | 30.8 | 33.2 | 35.8 |
Pharmaceutical Services | 28.4 | 29.6 | 26.3 | 25.7 |
Medical Services | 16.3 | 9.0 | 4.0 | 3.9 |
Segment assets (SGD K)
| Segment assets (SGD K) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Medical Support Services | 761 | 1,116 | 593 |
Business Support Services | 2,125 | 2,084 | 2,090 |
Pharmaceutical Services | 2,514 | 2,323 | 1,449 |
Medical Services | 383 | 279 | 0 |
Unallocated | 14,717 | 14,884 | 15,337 |
Income statement (SGD K)
| Income statement (SGD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue | 11,993 | 12,965 | 12,585 | 12,813 | 12,414 |
Other income | 1,619 | 652 | 538 | 309 | 1,083 |
Inventories and consumables used | 3,348 | 3,567 | 2,725 | 2,865 | 2,431 |
Changes in inventories (expense if positive) | 78 | -84 | 183 | 20 | 27 |
Gross profit (derived) | 8,567 | 9,482 | 9,677 | 9,928 | 9,956 |
Employee benefits expense | 4,490 | 5,268 | 5,346 | 5,202 | 5,273 |
Depreciation and amortisation | 650 | 771 | 723 | 553 | 532 |
Other expenses | 1,460 | 2,147 | 3,295 | 1,546 | 2,901 |
Goodwill impairment (included in other expenses) | 339 | 0 | 0 | 261 | 1,596 |
Finance costs | 86 | 67 | 55 | 46 | 41 |
Share of JV results | -3 | 76 | 174 | 68 | 141 |
EBIT (derived) | 3,352 | 2,110 | 1,071 | 3,029 | 2,462 |
EBITDA (derived) | 4,002 | 2,881 | 1,794 | 3,582 | 2,994 |
Profit before tax | 3,266 | 2,043 | 1,016 | 2,983 | 2,421 |
Income tax | 370 | 354 | 149 | 151 | 196 |
Net profit (total) | 2,896 | 1,689 | 867 | 2,832 | 2,225 |
Net profit attributable to owners | 2,807 | 1,699 | 1,033 | 2,834 | 2,224 |
Adjusted net profit (derived) | 2,501 | 2,505 | 2,568 | 3,071 | 3,037 |
Per-share data (S$ cents)
| Per-share data (S$ cents) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EPS basic | 2.14 | 1.28 | 0.78 | 2.14 | 1.67 |
EPS diluted | 2.14 | 1.28 | 0.78 | 2.14 | 1.67 |
Dividend per share (declared for the year) | 1.68 | 1.68 | 1.68 | 1.68 | 1.68 |
Payout ratio, % (derived DPS/EPS) | 78.5 | 131.3 | 215.4 | 78.5 | 100.6 |
NAV per share | 13.32 | 13.40 | 12.15 | 12.60 | 12.28 |
Margins (%) — derived
| Margins (%) — derived | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin | 71.4 | 73.1 | 76.9 | 77.5 | 80.2 |
EBIT margin | 27.9 | 16.3 | 8.5 | 23.6 | 19.8 |
EBITDA margin | 33.4 | 22.2 | 14.3 | 28.0 | 24.1 |
Pre-tax margin | 27.2 | 15.8 | 8.1 | 23.3 | 19.5 |
Net margin (total profit) | 24.1 | 13.0 | 6.9 | 22.1 | 17.9 |
Adjusted net margin | 20.9 | 19.3 | 20.4 | 24.0 | 24.5 |
Effective tax rate | 11.3 | 17.3 | 14.7 | 5.1 | 8.1 |
Growth (%) — derived (%)
| Growth (%) — derived (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Revenue growth | 8.1 | -2.9 | 1.8 | -3.1 |
Adjusted net profit growth | 0.2 | 2.5 | 19.6 | -1.1 |
Reported attributable profit growth | -39.5 | -39.2 | 174.4 | -21.5 |
Balance Sheet
| Balance sheet (SGD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 22,981 | 22,595 | 20,500 | 20,686 | 19,469 |
Cash and bank balances | 5,823 | 3,634 | 3,170 | 3,476 | 3,524 |
Fixed deposits | 516 | 518 | 2,000 | 2,079 | 2,000 |
Cash and fixed deposits | 6,339 | 4,152 | 5,170 | 5,555 | 5,524 |
Financial assets at FVTPL | 5,573 | 4,757 | 2,468 | 2,483 | 2,722 |
Bank borrowings — current | 496 | 496 | 506 | 516 | 262 |
Bank borrowings — non-current | 1,779 | 1,283 | 778 | 262 | 0 |
Total bank borrowings | 2,275 | 1,779 | 1,284 | 778 | 262 |
Lease liabilities (total) | 829 | 560 | 801 | 888 | 734 |
Net cash excl. leases (derived) | 4,064 | 2,373 | 3,886 | 4,777 | 5,262 |
Net cash incl. leases (derived) | 3,235 | 1,813 | 3,085 | 3,889 | 4,528 |
Goodwill | 6,505 | 9,269 | 8,686 | 8,425 | 6,747 |
Total intangible assets | 6,686 | 9,569 | 8,841 | 8,504 | 6,747 |
Investment in joint ventures | 208 | 284 | 458 | 464 | 605 |
Current assets | 9,393 | 7,040 | 7,802 | 8,311 | 8,492 |
Current liabilities | 3,240 | 3,197 | 3,035 | 3,203 | 2,429 |
Working capital (derived) | 6,153 | 3,843 | 4,767 | 5,108 | 6,063 |
Total liabilities | 5,505 | 4,812 | 4,342 | 3,959 | 2,950 |
Equity attributable to owners | 17,253 | 17,570 | 16,118 | 16,720 | 16,519 |
Non-controlling interests | 223 | 213 | 40 | 7 | 0 |
Total equity | 17,476 | 17,783 | 16,158 | 16,727 | 16,519 |
Cgu Details
| CGU | Goodwill at 31 Mar 2026 (SGD K) |
|---|---|
Carlin | 2,764 |
MDX Advisory | 1,068 |
MDX/Medinex Professional Services | 914 |
Ark Leadership & Learning | 872 |
Nex Healthcare (after S$1,596k impairment) | 794 |
AccTax | 335 |
Cash flow (SGD K)
| Cash flow (SGD K) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | 2,856 | 3,028 | 2,697 | 3,350 | 2,708 |
Capex (PPE + intangibles) | 230 | 193 | 30 | 23 | 158 |
Free cash flow (derived: OCF − capex) | 2,626 | 2,835 | 2,667 | 3,327 | 2,550 |
Lease principal repayments | 494 | 483 | 300 | 399 | 419 |
FCF after lease principal (derived) | 2,132 | 2,352 | 2,367 | 2,928 | 2,131 |
Dividends paid to owners | 2,204 | 1,977 | 2,481 | 2,229 | 2,238 |
Dividends paid to non-controlling interests | 135 | 0 | 0 | 24 | 8 |
Share buybacks | 0 | 0 | 0 | 0 | 602 |
Acquisitions (net cash outflow, incl. advances) | 300 | 2,334 | 0 | 0 | 0 |
Disposal proceeds (subsidiaries + FVTPL) | 856 | 0 | 1,844 | 0 | 609 |
Net bank borrowing repayment | 235 | 496 | 496 | 506 | 516 |
Ratios — derived
| Ratios — derived | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, % (attributable profit / average owners' equity) | 16.6 | 9.8 | 6.1 | 17.3 | 13.4 |
ROA, % (net profit / year-end total assets) | 12.6 | 7.5 | 4.2 | 13.7 | 11.4 |
ROIC, % (EBIT × 0.83 / [equity + debt + leases − cash]) | 19.5 | 11.0 | 6.8 | 19.6 | 17.0 |
Current ratio, x | 2.90 | 2.20 | 2.57 | 2.59 | 3.50 |
Debt/equity, x (bank borrowings) | 0.13 | 0.10 | 0.08 | 0.05 | 0.02 |
Debt incl. leases/equity, x | 0.18 | 0.13 | 0.13 | 0.10 | 0.06 |
Net debt/EBITDA, x (negative = net cash) | -1.02 | -0.82 | -2.17 | -1.33 | -1.76 |
Interest coverage, x (EBIT / finance costs) | 39.0 | 31.5 | 19.5 | 65.8 | 60.0 |
Asset turnover, x (revenue / year-end assets) | 0.52 | 0.57 | 0.61 | 0.62 | 0.64 |
DSO, days (net trade receivables / revenue × 365) | 61.4 | 57.1 | 53.0 | 57.2 | 67.3 |
DIO, days (inventory / inventories used × 365) | 51.6 | 59.5 | 48.3 | 46.2 | 49.7 |
DPO, days (aggregator trade payables / inventories used × 365) | 44.7 | 49.3 | 47.7 | 40.5 | 37.1 |
Cash conversion cycle, days | 68.3 | 67.3 | 53.6 | 62.9 | 79.9 |
Geographic revenue (SGD K)
| Geographic revenue (SGD K) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Group | 12,585 | 12,813 | 12,414 |
Capital Markets
| Item | Value | Source |
|---|---|---|
Share price | S$0.200 | StockAnalysis (aggregator) |
52-week range | S$0.190 – S$0.255 | StockAnalysis (aggregator) |
Other observed prices | S$0.20 (around May 2024, Google Finance); S$0.23 (24 Jul 2026, StockAnalysis) | Aggregators |
Shares outstanding | 134,543,843 | FY2026 results |
Market capitalisation | S$26.9m | Derived |
Enterprise value (market cap − cash and FD + bank debt + leases) | S$22.4m | Derived |
EV also excluding quoted investments | S$19.7m | Derived |
Valuation multiple — derived (FY2026 basis) | Value | — |
P/E, trailing (attributable profit S$2.224m) | 12.1x (StockAnalysis shows 11.98x) | — |
P/E on adjusted net profit (S$3.04m) | 8.9x | — |
P/B (NAV 12.28 cents) | 1.63x | — |
EV/EBITDA (S$2.99m) | 7.5x | — |
EV/Sales | 1.8x | — |
Dividend yield (1.68 cents) | 8.4% | — |
Dividend history
| Dividend history | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
DPS declared (S$ cents) | 1.68 | 1.68 | 1.68 | 1.68 | 1.68 |
Dividends paid to owners (SGD K) | 2,204 | 1,977 | 2,481 | 2,229 | 2,238 |
Share buybacks (SGD K) | 0 | 0 | 0 | 0 | 602 |
Debt maturity (SGD K)
| Debt maturity (SGD K) | Due within 1 year | Due after 1 year |
|---|---|---|
Bank borrowings (Term loan I, unsecured, fixed rate) | 262 | 0 |
Lease liabilities | 249 | 485 |
Analyst Conclusions
Management guidance
Medinex does not give quantitative guidance. Its qualitative outlook (FY2026 results and AR2026) expects the next 12 months to be shaped by:
-
the IP regulatory tightening and its knock-on effect on private specialists;
-
continued consolidation and pricing pressure;
-
AI-driven margin compression in transactional services.
Its response is to move to higher-value advisory, adopt AI and digital tools, and keep integrating its workforce. There are no consensus estimates.
Bull case
-
Underlying profitability is rising, not falling. Adjusted net profit (derived) went from about S$2.5m in FY2022–FY2024 to about S$3.0–3.1m in FY2025–FY2026, and management's pre-impairment profit grew 24% in FY2026. On adjusted earnings the stock trades at about 9x, or about 6x after deducting liquid assets.
-
Balance sheet and dividend. Net cash of S$5.3m plus S$2.7m of quoted investments equals about 31% of market capitalisation. Operating cash flow of about S$2.7–3.4m a year supports a dividend yield of about 8.4%.
-
The weak parts are mostly gone. Medical Services has been exited and Nex goodwill written down to S$0.79m. Office consolidation and a falling headcount (73 to 65) set up margin gains once revenue stabilises.
Bear case
-
Revenue is shrinking at the edges. Losing the Nex contract in July 2026 could cut further into Pharmaceutical Services revenue (S$2.79m in FY2026). Business Support growth stalled in FY2026 (−0.1%). Group revenue has grown at only 0.9% a year since FY2022.
-
Structural pressure on the client base. IP tightening and clinic consolidation directly threaten the independent specialists and GPs who drive clinic set-up and compliance revenue. AI-native bookkeeping competitors threaten pricing in Business Support.
-
Dividend cover is thin, and goodwill is still at risk. FCF after lease payments (S$2.13m in FY2026) was below dividends paid (S$2.25m). The remaining S$6.75m of goodwill relies on FY2026's lower discount rates (8.6–11.3%, down from 14%), so any further shortfall could bring more impairments.
Catalysts and monitorables (next 12 months)
| Monitorable | Timing | What to watch |
|---|---|---|
| 1H FY2027 results | Around mid-Nov 2026 (expected) | Pharmaceutical revenue after the Nex contract expiry; whether the interim dividend stays at 0.84 cents |
| FY2027 full-year results | Around May 2027 (expected) | Goodwill testing of Carlin and MDX CGUs; adjusted profit relative to the S$2.2m+ dividend outlay |
| Impact of IP regulation | FY2027 | Demand for MHC clinic set-up projects |
| Digitisation milestones | By 31 Mar 2027 | Completion of the online tax and compilation migration; e-signing; Data Protection Trustmark |
| Office consolidation | FY2027 | Reduction from 4 to 3 sites |
| Use of capital | Ongoing | Bolt-on M&A from S$5.3m net cash and S$0.47m of unutilised IPO proceeds; use of the buyback mandate |
| Investment portfolio | Ongoing | FVTPL valuation swings on S$2.7m of quoted equities |
Analyst verdict
Medinex is a small, cash-generative, high-margin professional-services platform. Its reported earnings understate a fairly steady core, but that core is not growing. Over FY2022–FY2026, revenue was flat at about S$12–13m. Meanwhile, the mix shifted decisively towards fee-based Medical Support and Business Support services, which now make up 73.5% of revenue and nearly all segment profit. Underlying profit, after stripping out investment fair-value swings, disposal results and goodwill impairments, has been S$2.5–3.1m a year. The FY2026 headline decline of 21.5% in attributable profit reflects a S$1.60m non-cash goodwill write-down on Nex Healthcare, not a collapse in operations.
The investment question is whether the professional-services core can at least hold its ground as three headwinds converge. First, tighter Integrated Shield Plan rules since April 2026 hit the private specialists Medinex serves. Second, clinic consolidation removes independent doctors from its client pool. Third, AI-led competitors are eroding bookkeeping prices. Management's answer is to move up the value chain, digitise and consolidate offices. That is sensible, but it is also generic and lacks measurable targets.
Valuation already reflects much of this. At about S$0.20 the stock trades at about 12x reported and about 9x adjusted earnings, 1.6x book and about 7.5x EV/EBITDA. It yields about 8.4%, and liquid assets cover about 31% of the market value. The main risk to that yield is that FCF after lease payments roughly equals the dividend. A further revenue decline from the Nex contract expiry and the IP changes could therefore force a cut. The stock is also thinly traded and has no analyst coverage.
Overall assessment: neutral, income-oriented. The case rests on dividend sustainability and cash backing rather than growth. The 1H FY2027 results due in November 2026 are the key test of whether underlying profit can absorb the loss of the Nex contract.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Committees | Background and education |
|---|---|---|---|---|
Tan Lee Meng | Non-Executive Chairman (described as non-independent in the 2026 AGM results) | 22 May 2017; re-elected 24 Jul 2026 | Member of AC, NC and RC | Investor and incubator. Set up LinksTech Holding (2000). Former director of Asia Progress International. Former independent director of BRC Asia and Hisaka Holdings (now Regal International); former non-executive director of See Hup Seng (now SHS Holdings). BSc summa cum laude, Oklahoma City University (1993); MBA (Investment and Finance), University of Hull |
Jessie Low Mui Choo | Executive Director and CEO | 1 Jun 2017; re-elected 24 Jul 2026 | Attends AC, NC and RC meetings by invitation | Audit assistant at Ernst & Young (1990). Head of internal audit at Pan Malayan Holdings (1995). Founded El-Shaddai Consultants (1996) and JK Corporate Services (2003). Registered Ark Assurance (2005). Principal partner at Ark Alliance LLP (2014–2017). Lead Independent Director of Medtecs International. MBA, University of Adelaide; Registered Public Accountant; FCA (ISCA); ACCA member; Accredited Tax Practitioner |
Lim Tai Toon | Lead Independent Non-Executive Director | 14 Nov 2018; re-elected 25 Jul 2025 | Chairs AC; member of NC and RC | 14 years in the Singapore Armed Forces (including Army Budget Controller). Head of Corporate Affairs at Ipco International. Chairman and MD of Startech Electronics. Executive Director of Eastgate Technology. Chairman of Ark Lanka Holdings and Food Studio. Former Lead Independent Director of Medtecs (2010–2024). B.Acc, NUS (1985); MBA, Brunel; Master of Business IT, Curtin |
Ye Binlin | Independent Non-Executive Director | 1 Sep 2020; re-elected 25 Jul 2025 | Chairs RC; member of NC and AC | CFO and chief accountant for COSCO group companies (2001–2014). Executive Director and CFO of AnAn International (2017–2018). Independent director of Emerging Towns & Cities Singapore. BEcon, Shanghai Maritime University; Senior Accredited Director, Singapore Institute of Directors |
Venkata Subramanian s/o Sreenivasan | Independent Non-Executive Director | 23 Aug 2021; re-elected 25 Jul 2024 | Chairs NC; member of RC and AC | Economist at the National Productivity Board (1987). Senior correspondent and news editor at The Business Times (1993–2017). Executive Editor, SPH Radio (2017–2021). Associate Editor, The Straits Times (2021–). BA (Economics and Political Science), Brandon University; MA (Economics), University of Manitoba |
Executive Leadership Team
| Name | Title | Background |
|---|---|---|
Jessie Low Mui Choo | CEO | See board table |
Lee Kim Hung | Chief Operating Officer; heads Nex Healthcare operations | SAF (1993–2010). ST Kinetics (2010–2011). CEO of the Singapore Badminton Association (2011–2013). COO, then CEO, of Northeast Health International (from 2013). MBA, NTU; MSc, University of Central Florida; BEng (First Class, Aeronautical), University of London |
Low Siam Kiang | Financial Controller | Joined 2010. Chief Integration Officer from June 2022; re-appointed FC on 16 January 2024. Director of most subsidiaries. Accredited Tax Practitioner; CA (ISCA) |
Valerie Low (Low Mui Keow), age 54 | Chief Business Development Officer; MD of Ark LL; ESG Lead Facilitator | Former Vice President at UOB; former regional talent lead at FedEx. Founded Ark LL in 2014. MA, George Washington University; BA, NUS. Sister of the CEO |
Chai Yee Hoi | Chief Tax Officer; director of AccTax | Inland Revenue Department (1986). IRAS tax audit (from 1993). GST Manager at Ernst & Young (2000). GST Consultant at Robin Chia & Co. (2005). Founded AccTax in 2006. Accredited Tax Advisor; FCCA |
Directors' Remuneration
| Item | Detail | Source |
|---|---|---|
Directors' fees approved for FY2027 | S$106,250 in aggregate, payable quarterly in arrears | Results of AGM, 24 July 2026 |
CEO and key management remuneration (salary, bonus, stock, total) | Catalist companies typically disclose remuneration in bands. | — |
Share plans | Medinex Performance Share Plan and Medinex Employee Share Option Scheme; issuance mandates renewed at the 2026 AGM. No options outstanding at 31 March 2026. | AGM results; FY2026 results Note 17 |
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
Other substantial shareholders, top 20 holders, free float | AR2026 "Statistics of Shareholding" (p. | — |
Institutional ownership (top 10) | Not publicly disclosed; no institutional holders identified | — |
Treasury shares | Nil at 31 March 2026 | FY2026 results Note 17 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Positioning relative to Medinex |
|---|---|---|---|
Business Support | Boardroom (Singapore) | Private; formerly SGX-listed | Larger, regional corporate secretarial and share registry provider |
Business Support | Tricor (Singapore) | Private, regional | Larger, regional corporate services and payroll provider |
Business Support | Sleek | Private, digital | Low-cost online incorporation and accounting; part of the pricing pressure management cites |
Business Support | Osome | Private, digital | AI and app-led bookkeeping; part of the AI disruption threat |
Business Support | In.Corp / Acclime | Private, regional | Corporate services for SMEs and foreign investors |
Business Support | Small local accounting and secretarial firms | Fragmented | FY2025 commentary notes many smaller low-cost players |
Medical Support | Clinic-consultancy firms and in-house practice managers of larger groups | Fragmented / private | Consolidation of clinics into larger groups internalises these services |
Medical Support / clinics | Fullerton Health, Healthway Medical, Raffles Medical Group (SGX-listed) | Large healthcare groups | Acquirers of independent practices, which shrinks Medinex's addressable market of standalone clinics |
Pharmaceutical | Zuellig Pharma, DKSH (healthcare), local wholesalers | Large distributors | Medinex procures from authorised distributors such as these and resells; it has little scale advantage |
Medical Services (exited) | Fullerton Health, Raffles Medical, specialist screening and pre-employment centres | Large providers | Explains why Medinex exited the segment |
Competitor Detail
| Metric (latest fiscal year) | Medinex FY2026 |
|---|---|
Revenue | S$12.4m |
Revenue growth | -3.1% |
Net margin | 17.9% (adjusted 24.5%) |
R&D intensity | 0% |
Recent Developments
As a Catalist micro-cap, Medinex issues few material announcements.



